EA030564B9 - СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ СИСТЕМУ 1,1',2,5'-ТЕТРАГИДРОСПИРО[ИНДОЛ-3,2'-ПИРРОЛ]-2,5'-ДИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ p53-Mdm2 - Google Patents

СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ СИСТЕМУ 1,1',2,5'-ТЕТРАГИДРОСПИРО[ИНДОЛ-3,2'-ПИРРОЛ]-2,5'-ДИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ p53-Mdm2

Info

Publication number
EA030564B9
EA030564B9 EA201692550A EA201692550A EA030564B9 EA 030564 B9 EA030564 B9 EA 030564B9 EA 201692550 A EA201692550 A EA 201692550A EA 201692550 A EA201692550 A EA 201692550A EA 030564 B9 EA030564 B9 EA 030564B9
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
tetrahydrospiro
indole
pyrrole
inhibitors
Prior art date
Application number
EA201692550A
Other languages
English (en)
Other versions
EA201692550A1 (ru
EA030564B1 (ru
Inventor
Марцин Федер
Ивона Калиновская
Иоанна Адриана Ящевская
Эва Бурхард
Войцех Левандовский
Уршула Бульковская
Мария Мазур
Катаржина Вос-Лятоси
Original Assignee
Адамед Сп. З О.О.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адамед Сп. З О.О. filed Critical Адамед Сп. З О.О.
Publication of EA201692550A1 publication Critical patent/EA201692550A1/ru
Publication of EA030564B1 publication Critical patent/EA030564B1/ru
Publication of EA030564B9 publication Critical patent/EA030564B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Спирооксоиндольное соединение, представленное формулой, выбранной из группы, состоящей из формулы (IA) и (IB), где все символы являются такими, как определено в настоящем описании. Соединение можно применять в способе предотвращения и/или лечения заболеваний, выбранных из группы, состоящей из рака, иммунных заболеваний, воспалительных состояний, аллергических кожных заболеваний, связанных с чрезмерной пролиферацией, и вирусных инфекций.
EA201692550A 2014-06-12 2015-06-11 СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ СИСТЕМУ 1,1',2,5'-ТЕТРАГИДРОСПИРО[ИНДОЛ-3,2'-ПИРРОЛ]-2,5'-ДИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ p53-Mdm2 EA030564B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL40854014 2014-06-12
PCT/IB2015/054425 WO2015189799A1 (en) 2014-06-12 2015-06-11 Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction

Publications (3)

Publication Number Publication Date
EA201692550A1 EA201692550A1 (ru) 2017-07-31
EA030564B1 EA030564B1 (ru) 2018-08-31
EA030564B9 true EA030564B9 (ru) 2019-02-28

Family

ID=54832985

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692550A EA030564B9 (ru) 2014-06-12 2015-06-11 СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ СИСТЕМУ 1,1',2,5'-ТЕТРАГИДРОСПИРО[ИНДОЛ-3,2'-ПИРРОЛ]-2,5'-ДИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ p53-Mdm2

Country Status (13)

Country Link
US (1) US20170129903A1 (ru)
EP (1) EP3154982B1 (ru)
JP (1) JP2017517555A (ru)
KR (1) KR20170012559A (ru)
CN (1) CN106795168A (ru)
AU (1) AU2015273106A1 (ru)
BR (1) BR112016028888A2 (ru)
CA (1) CA2947134A1 (ru)
EA (1) EA030564B9 (ru)
IL (1) IL248839A0 (ru)
MX (1) MX2016016363A (ru)
WO (1) WO2015189799A1 (ru)
ZA (1) ZA201700110B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
EP3558302A4 (en) 2016-12-21 2020-07-15 Board of Regents of the University of Nebraska DIMERS OF COVALENTS NFKB INHIBITORS
KR20200105837A (ko) * 2017-12-29 2020-09-09 간 앤 리 파마슈티칼스 종양 억제제로 사용될 수 있는 화합물 및 이의 제조방법과 용도
EP3511334A1 (en) 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
KR102039696B1 (ko) 2018-04-23 2019-11-04 충남대학교산학협력단 세포내 결핵균 제어를 위한 p53 발현 조절 가능한 조성물 (K279-1558) 또는 방법
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN114057756B (zh) * 2021-12-10 2022-12-09 山东第一医科大学(山东省医学科学院) 一种抗肿瘤活性的吡咯烷基螺氧化吲哚类化合物及其合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2314100T3 (es) 2001-05-03 2009-03-16 Monsanto Technology Llc Derivados de piruvato.
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
JP5207964B2 (ja) 2006-03-31 2013-06-12 武田薬品工業株式会社 酸分泌抑制薬
EP2076514A1 (en) 2006-10-12 2009-07-08 Xenon Pharmaceuticals Inc. Spiro (furo ý3, 2-c¨pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
US8466188B2 (en) 2006-10-12 2013-06-18 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
US8217044B2 (en) * 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
AU2012226890B2 (en) 2011-03-10 2016-10-06 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivative
AU2012253339B2 (en) 2011-05-11 2016-03-31 Sanofi Spiro-oxindole MDM2 antagonists

Also Published As

Publication number Publication date
CA2947134A1 (en) 2015-12-17
WO2015189799A1 (en) 2015-12-17
EP3154982A1 (en) 2017-04-19
ZA201700110B (en) 2018-04-25
AU2015273106A1 (en) 2016-11-17
MX2016016363A (es) 2017-04-06
EA201692550A1 (ru) 2017-07-31
KR20170012559A (ko) 2017-02-02
JP2017517555A (ja) 2017-06-29
BR112016028888A2 (pt) 2017-08-22
CN106795168A (zh) 2017-05-31
US20170129903A1 (en) 2017-05-11
EA030564B1 (ru) 2018-08-31
EP3154982B1 (en) 2018-05-02
IL248839A0 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
EA030564B9 (ru) СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ СИСТЕМУ 1,1',2,5'-ТЕТРАГИДРОСПИРО[ИНДОЛ-3,2'-ПИРРОЛ]-2,5'-ДИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ p53-Mdm2
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
IL251285A0 (en) 3-substituted 5-amino-h6-triazolo[5,4-d]pyrimidine-7,2-dione compounds for the treatment and prevention of viral infection
HK1218116A1 (zh) 用於治療病毒感染和其他疾病的吡咯並 嘧啶衍生物
NZ712453A (en) Tricyclic heterocycles as bet protein inhibitors
GEP201706686B (en) Novel pyrrole compounds, preparation method thereof, and pharmaceutical compositions containing them
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
AU2015352440B2 (en) Compounds
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
PH12015502564A1 (en) Pyridone derivatives for the treatment of viral infections and further diseases
IN2013MU03216A (ru)
EA201500942A1 (ru) ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН
WO2014176068A3 (en) Treatment and prevention of bacterial skin infections using oritavancin
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
UA66165U (ru) Применение витаминной композиции, которая содержит витамины С и К3, в качестве средства для лечения вирусных инфекций

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU